Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine
- PMID: 2475500
Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine
Erratum in
- J Biol Chem 1990 Mar 5;265(7):4172
Abstract
Cells that express P-glycoprotein are resistant to many unrelated anticancer drugs. All evidence suggests that P-glycoprotein is a plasma membrane protein that confers multidrug resistance by actively transporting these cytotoxic drugs out of cells. The objective of our work is to locate drug binding sites on P-glycoprotein. Azidopine is a photoaffinity drug analog that specifically labels P-glycoprotein. To determine the region of P-glycoprotein that binds azidopine, we labeled P-glycoprotein with azidopine and digested the labeled protein into fragments. We then identified the labeled fragments with specific antibodies. We have determined that azidopine labels two different regions of P-glycoprotein: one region is in the amino half of P-glycoprotein, and the other is in the carboxyl half of the protein. Our results suggest that P-glycoprotein contains either two binding sites for azidopine or a single site formed by the two homologous halves of the protein.
Similar articles
-
Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies.J Biol Chem. 1989 Sep 25;264(27):16282-91. J Biol Chem. 1989. PMID: 2476441
-
Characterization of the azidopine and vinblastine binding site of P-glycoprotein.J Biol Chem. 1992 Oct 15;267(29):21020-6. J Biol Chem. 1992. PMID: 1356986
-
Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins.Biochem Pharmacol. 1988 Apr 1;37(7):1417-21. doi: 10.1016/0006-2952(88)90803-9. Biochem Pharmacol. 1988. PMID: 2895656 No abstract available.
-
Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells.Cancer Invest. 1993;11(1):46-56. doi: 10.3109/07357909309020260. Cancer Invest. 1993. PMID: 8093677 Review. No abstract available.
-
Photoaffinity labeling of P-glycoprotein.Mini Rev Med Chem. 2005 Feb;5(2):165-72. doi: 10.2174/1389557053402738. Mini Rev Med Chem. 2005. PMID: 15720286 Review.
Cited by
-
Role of P-glycoprotein in pharmacokinetics: clinical implications.Clin Pharmacokinet. 2003;42(1):59-98. doi: 10.2165/00003088-200342010-00003. Clin Pharmacokinet. 2003. PMID: 12489979 Review.
-
Aptamer-functionalized Hybrid Nanoparticles to Enhance the Delivery of Doxorubicin into Breast Cancer Cells by Silencing P-glycoprotein.J Cancer Treatment Diagn. 2020;4(1):1-13. doi: 10.29245/2578-2967/2020/1.1176. J Cancer Treatment Diagn. 2020. PMID: 32395707 Free PMC article.
-
Molecular analysis of the multidrug transporter, P-glycoprotein.Cytotechnology. 1998 Sep;27(1-3):31-60. doi: 10.1023/A:1008023629269. Cytotechnology. 1998. PMID: 19002782 Free PMC article.
-
Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.Eur J Pharm Biopharm. 2017 May;114:108-118. doi: 10.1016/j.ejpb.2017.01.011. Epub 2017 Jan 25. Eur J Pharm Biopharm. 2017. PMID: 28131717 Free PMC article.
-
P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.Drugs Aging. 1995 Jul;7(1):19-29. doi: 10.2165/00002512-199507010-00003. Drugs Aging. 1995. PMID: 7579778 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources